<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146120</url>
  </required_header>
  <id_info>
    <org_study_id>AMLHD98A</org_study_id>
    <nct_id>NCT00146120</nct_id>
  </id_info>
  <brief_title>Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result</brief_title>
  <official_title>Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <brief_summary>
    <textblock>
      The concept of the investigators risk-adapted multicenter treatment trial for younger adults,
      AML HD98A, is based on the results of the AML HD93 trial and on published data. Definition of
      risk groups is different compared to the AML HD93 trial; high-risk: refractory disease after
      first induction therapy and/or high risk karyotype [abn(3q), -5/5q-, -7/7q-, abn(12p),
      abn(17p), complex]; intermediate-risk: complete remission after induction therapy and
      intermediate risk karyotype [normal, abn(11q23), abn(16q22), other rare aberrations];
      low-risk: complete remission after induction therapy and low risk karyotype [t(8;21)].
      Patients exhibiting a t(15;17) were treated in a separated trial (APL HD95). Treatment
      consists of a first induction therapy with ICE followed by a second cycle ICE in case of
      response to first induction therapy. Patients with refractory disease after first induction
      therapy are assigned to a salvage therapy with A-HAM (all-trans retinoic acid, high-dose
      cytarabine and mitoxantrone) and the search for potential hematopoietic stem cell donors is
      extended from the family to unrelated persons. All patients achieving a CR after induction
      therapy with ICE are assigned to a first consolidation therapy with HAM. For
      intermediate-risk patients a peripheral stem cell or a bone marrow harvest are intended
      during the hematological recovery after the first consolidation. Second consolidation therapy
      was stratified according to the risk definition. For high risk patients a allogeneic
      transplantation is assigned from a related or unrelated donor preferentially after a
      dose-intensified conditioning therapy. All patients with intermediate risk and an HLA-matched
      family donor are assigned to allogeneic transplantation. Intermediate-risk patients without a
      family donor and normal karyotype at diagnosis are randomized between an autologous stem cell
      transplantation and a second course of HAM. The other intermediate-risk patients are assigned
      to autologous transplantation. For low-risk patients a second course of HAM is assigned.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytosin-Arabinosid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans Retinoid acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML, de Novo or secondary after Myelodysplasy, or with therapy-induced
             AML after healed primary malignom; or refractory anemia with excess of blasts in
             transformation (RAEB-t); the diagnosis must be confirmed morphological, cytochemical
             and with immunological phenotyping

          -  Cytogenetical tests must be performed for each patient

          -  Age: 16 - 60 years

          -  All patients have to be informed about the character of the study. Written informed
             consent of each patient at study entry.

        Exclusion Criteria:

          -  Organic insufficiency: Insufficiency of the kidneys (Crea &gt; 1.5 x upper normal serum
             level), or insufficiency of the liver (bilirubin, SGOT or AP &gt; 2 x upper normal serum
             level) uncaused by the AML; severe obstruction or restrictive ventilation disorder,
             heart failure with a ejection fraction &lt; 0.5

          -  Secondary malignom

          -  Other severe diseases

          -  Pregnancy

          -  Participation in an concurrent clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Döhner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine III, University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology / Oncology, University Hospital of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medical Department, Hematology and Oncology Center, Hanuschhospital Wien</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General Internal Medicine, University Hospital of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Hematology, Heinrich-Heine University</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine III, City Hospital Frankfurt Am Main - Höchst</name>
      <address>
        <city>Frankfurt</city>
        <zip>65927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department IV, University of Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine, Wilhelm-Anton-Hospital Goch</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Interial Medicine, University of Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department III of Hematology and Oncology, General Hospital Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine V, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine I, University Hospital of Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department II, City Hospital Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department II, University Hospital of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine /Hematology and Oncology, Caritas Hospital Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medical Department, City Hospital München-Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department III, Clinical Center rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology and Oncology, City Hospital Neunkirchen gGmbH</name>
      <address>
        <city>Neunkirchen</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology and Oncology, Clinical Center of Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematologie and Oncology, Caritas Hospital St. Theresa Saarbrücken</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinikal Cetner of Stuttgart, Center of Oncology</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department I, Clinical Center of Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Barmherzige Brüder, I Medical Department</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Reinhard Marre</name_title>
    <organization>University of Ulm</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

